insights_auto
Perché BT3 è in calo 9,09%?
Approfondiscichevron_right
BT3:FRA
BioTime
0,81 €
arrow_downward
-9,09%(-0,081) 1G
6 nov, 08:04:38 GMT+1 · EUR
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per BT3 in corso…
Apertura
0,81 €
Massimo
0,81 €
Minimo
0,81 €
Cap. mercato
248,63 Mln
Vol. medio
137,00
Volume
0,00
Max 52 sett.
1,68 €
Min 52 sett.
0,78 €
N. di dipendenti
75
Apertura
0,81 €
Massimo
0,81 €
Minimo
0,81 €
Cap. mercato
248,63 Mln
Vol. medio
137,00
Volume
0,00
Max 52 sett.
1,68 €
Min 52 sett.
0,78 €
N. di dipendenti
75
Articoli giornalistici
Da fonti web e partner giornalistici
Profilo
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Informazioni su BioTime